{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-064729","form_type":"8-K","ticker":"SEPN","cik":"0001984086","company_name":"Septerna, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.717147+00:00","generated_at":"2026-05-24T04:23:47.350514+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Septerna reports FY2024 net loss of $71.8M, discontinues SEP-786 Phase 1 trial","bullets":["Discontinued SEP-786 Phase 1 trial after two Grade 3 elevated unconjugated bilirubin events, reversible without liver injury.","Plans to select a next-generation oral PTH1R agonist candidate by end of 2025 to advance toward clinic.","SEP-631 MRGPRX2 NAM program on track to initiate Phase 1 trial in 2025 for mast cell diseases.","Cash, equivalents, and marketable securities $420.8M at Dec 31, 2024; runway into early 2028.","Appointed Gil Labrucherie as CFO in January 2025; net loss $20.7M in Q4 2024, $71.8M for FY2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-064729","json":"https://secwatch.observer/filing/0001193125-25-064729.json","markdown":"https://secwatch.observer/filing/0001193125-25-064729.md","text":"https://secwatch.observer/filing/0001193125-25-064729.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1984086/000119312525064729/0001193125-25-064729-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1984086/000119312525064729/d906388d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:23:47.350514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}